Literature DB >> 16313351

The role of the immune system in the pathophysiology of osteoporosis.

Jackie A Clowes1, B Lawrence Riggs, Sundeep Khosla.   

Abstract

The role of the immune system in the development of senile osteoporosis, which arises primarily through the effects of estrogen deficiency and secondary hyperparathyroidism, is slowly being unraveled. This review focuses on our current understanding of how the components of this complex-interlinked system are regulated and how these fit with previous models of senile and postmenopausal osteoporosis. There is certainly substantial evidence that bone remodeling is a tightly regulated, finely balanced process influenced by subtle changes in proinflammatory and inhibitory cytokines as well as hormones and cellular components that act primarily but not exclusively through the receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin system. In addition, an acute or chronic imbalance in the system due to infection or inflammation could contribute to systemic (or local) bone loss and increase the risk of fracture. Although significant progress has been made, there remains much to be done in unraveling this complex interaction between the immune system and bone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16313351     DOI: 10.1111/j.0105-2896.2005.00334.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  129 in total

1.  DXA surrogates for visceral fat are inversely associated with bone density measures in adolescent athletes with menstrual dysfunction.

Authors:  Kathryn E Ackerman; Brittany Davis; Leah Jacoby; Madhusmita Misra
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

2.  Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women.

Authors:  Dhananjay D Marathe; Anshu Marathe; Donald E Mager
Journal:  Biopharm Drug Dispos       Date:  2011-09-22       Impact factor: 1.627

Review 3.  Skeletal manifestations of treatment of breast cancer on premenopausal women.

Authors:  Loomee Doo; Charles L Shapiro
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

Review 4.  Proinflammatory cytokines and osteoporosis.

Authors:  Robert R McLean
Journal:  Curr Osteoporos Rep       Date:  2009-12       Impact factor: 5.096

5.  Denosumab in postmenopausal osteoporosis: what the clinician needs to know.

Authors:  E Michael Lewiecki
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-02       Impact factor: 5.346

6.  Aging and bone loss: new insights for the clinician.

Authors:  Oddom Demontiero; Christopher Vidal; Gustavo Duque
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-04       Impact factor: 5.346

7.  Osteoprotegerin exerts its pro-inflammatory effects through nuclear factor-κB activation.

Authors:  Lily Nahidi; Steven T Leach; Daniel A Lemberg; Andrew S Day
Journal:  Dig Dis Sci       Date:  2013-09-19       Impact factor: 3.199

8.  Inhibition of osteoblastic bone formation by nuclear factor-kappaB.

Authors:  Jia Chang; Zhuo Wang; Eric Tang; Zhipeng Fan; Laurie McCauley; Renny Franceschi; Kunliang Guan; Paul H Krebsbach; Cun-Yu Wang
Journal:  Nat Med       Date:  2009-06       Impact factor: 53.440

9.  Denosumab: an investigational drug for the management of postmenopausal osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Biologics       Date:  2008-12

Review 10.  Rapamycin and the transcription factor C/EBPbeta as a switch in osteoclast differentiation: implications for lytic bone diseases.

Authors:  Jeske J Smink; Achim Leutz
Journal:  J Mol Med (Berl)       Date:  2009-11-27       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.